Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 1% status confers therapeutic sensitivity to Cisplatin, Gemcitabine, Nivolumab in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1250mg/m^2) in combination with cisplatin (75mg/m^2) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.3).
This statement is based on a regulatory approval from the Health Service Executive:
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.3)